Vildagliptin is a highly selective and reversible substrate-like DPP-4 inhibitor that binds to and forms a complex with DPP-4 to inhibit DPP-4 activity, increase active glucagon peptide-1 (GLP-1) concentration, promote glucose-dependent insulin secretion from pancreatic β cells and simultaneously adjust the function of α cells to reduce glucagon levels during hyperglycemia (8) to achieve bidirectional regulation of blood sugar. The gene discussed is INS; the disease is Hyperglycemia.